𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Quantitative imaging of124I and86Y with PET

✍ Scribed by Mark Lubberink; Hans Herzog


Book ID
105964384
Publisher
Springer
Year
2011
Tongue
English
Weight
500 KB
Volume
38
Category
Article
ISSN
0340-6997

No coin nor oath required. For personal study only.

✦ Synopsis


The quantitative accuracy and image quality of positron emission tomography (PET) measurements with ^124^I and ^86^Y is affected by the prompt emission of gamma radiation and positrons in their decays, as well as the higher energy of the emitted positrons compared to those emitted by ^18^F. PET scanners cannot distinguish between true coincidences, involving two 511-keV annihilation photons, and coincidences involving one annihilation photon and a prompt gamma, if the energy of this prompt gamma is within the energy window of the scanner. The current review deals with a number of aspects of the challenge this poses for quantitative PET imaging. First, the effect of prompt gamma coincidences on quantitative accuracy of PET images is discussed and a number of suggested corrections are described. Then, the effect of prompt gamma coincidences and the increased singles count rates due to gamma radiation on the count rate performance of PET is addressed, as well as possible improvements based on modification of the scanner’s energy windows. Finally, the effect of positron energy on spatial resolution and recovery is assessed. The methods presented in this overview aim to overcome the challenges associated with the decay characteristics of ^124^I and ^86^Y. Careful application of the presented correction methods can allow for quantitatively accurate images with improved image contrast.


πŸ“œ SIMILAR VOLUMES


PET imaging of tumor angiogenesis in mic
✍ Tapan K. Nayak; Kayhan Garmestani; Kwamena E. Baidoo; Diane E. Milenic; Martin W πŸ“‚ Article πŸ“… 2010 πŸ› John Wiley and Sons 🌐 French βš– 407 KB

## Abstract Bevacizumab is a humanized monoclonal antibody that binds to tumor‐secreted vascular endothelial growth factor (VEGF)‐A and inhibits tumor angiogenesis. In 2004, the antibody was approved by the US Food and Drug Administration (FDA) for the treatment of metastatic colorectal carcinoma i